AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22127938 — intervention group
Group type: EXPERIMENTAL
Intervention: RFVE therapy in ischaemic group
Number of subjects: 80
Study 22127938 — intervention group
Group type: COMPARATOR
Intervention: TNR therapy in ischaemic group
Number of subjects: 80
Study 19359142 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 36
Study 19359142 — intervention group
Group type: EXPERIMENTAL
Intervention: Low saturated fat diet
Number of subjects: 36
Study 19359142 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination message (high fiber/low saturated fat)
Number of subjects: 36
Study 16903985 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH 4 mg daily (group A)
Number of subjects: 26
Study 16903985 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH 3 times per week (group B)
Number of subjects: 26
Study 16903985 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related side effects in group A
Number of subjects: 26
Study 16903985 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related side effects in group B
Number of subjects: 26
Study 15474855 — intervention group
Group type: EXPERIMENTAL
Intervention: Liebowitz Self‐Rated Disability Scale (LSRDS)
Number of subjects: 0
Study 15474855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician‐rated Disability Profile (DP)
Number of subjects: 0
Study 15474855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheehan Disability Scale (SDS)
Number of subjects: 0
Study 11743379 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (10 microg/kg/min)
Number of subjects: 54
Study 11743379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (10 ng/kg/min)
Number of subjects: 54
Study 11743379 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (5 mg/ml)
Number of subjects: 54
Study 11743379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (10%)
Number of subjects: 54
Study 11743379 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution
Number of subjects: 54
Study 11743379 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 54
Study 9500304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.62 g/kg)
Number of subjects: 27
Study 9500304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9500304 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 27
Study 8298418 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 70000
Study 2500472 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 393
Study 2500472 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and Nitroglycerin
Number of subjects: 393
Study 2500472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 393
Study 2500472 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without acute cardiac catheterization
Number of subjects: 393
Study 30455761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursed-lips Breathing (PLB) in COPD patients
Number of subjects: 60
Study 30455761 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 60
Study 27355751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pozzolana Biologic Silva cement (PBS)
Number of subjects: 12
Study 27355751 — intervention group
Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 12
Study 24944132 — intervention group
Group type: EXPERIMENTAL
Intervention: Football + diet (FDG)
Number of subjects: 44
Study 24944132 — intervention group
Group type: COMPARATOR
Intervention: Diet (DG)
Number of subjects: 44
Study 21996593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed actinomycin D (n=50)
Number of subjects: 75
Study 21996593 — intervention group
Group type: COMPARATOR
Intervention: 5-day methotrexate (n=25)
Number of subjects: 75
Study 21095278 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with COPD
Number of subjects: 138
Study 21095278 — intervention group
Group type: COMPARATOR
Intervention: Heart failure alone
Number of subjects: 138
Study 19260631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment with hemisuccinate of hydrocortisone or dexamethasone
Number of subjects: 23
Study 19260631 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without cortisone
Number of subjects: 23
Study 16444031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestarium (an angiotensin-converting enzyme inhibitor)
Number of subjects: 0
Study 16444031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestarium
Number of subjects: 0
Study 15314409 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week home-based pulmonary rehabilitation program (inspiratory muscle training, upper and lower extremity exercise, relaxation, and telephone visit)
Number of subjects: 34
Study 15314409 — intervention group
Group type: COMPARATOR
Intervention: Education about self-management strategies (Control)
Number of subjects: 34
Study 10475140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine/Naloxone (50 mg/4 mg)
Number of subjects: 12
Study 10475140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac (75 mg)
Number of subjects: 12
Study 10475140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 12
Study 10475140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac (25 mg)
Number of subjects: 12
Study 10475140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac (50 mg)
Number of subjects: 12
Study 10475140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2143687 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV + CYP 300 mg/m2
Number of subjects: 41
Study 2143687 — intervention group
Group type: COMPARATOR
Intervention: MCV alone
Number of subjects: 41
Study 2143687 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV + CYP 150 mg/m2
Number of subjects: 41
Study 2143687 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV + CYP 75 mg/m2
Number of subjects: 41
Study 322242 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine (200 mg)
Number of subjects: 0
Study 322242 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (600 mg)
Number of subjects: 0
Study 31989843 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency ureteroscopy (URS) with intracorporeal lithotripsy
Number of subjects: 124
Study 31989843 — intervention group
Group type: COMPARATOR
Intervention: Double‐J ureteral stent insertion
Number of subjects: 124
Study 31370958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 176
Study 31370958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 31370958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 176
Study 27865004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 41
Study 27865004 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 41
Study 26400023 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (15 mg/m² every 8 h for 3 days)
Number of subjects: 75
Study 26400023 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 75
Study 26400023 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (in patients with acute myeloid leukemia (AML) with ≥20 % blasts)
Number of subjects: 75
Study 26400023 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) (in patients with acute myeloid leukemia (AML) with ≥20 % blasts)
Number of subjects: 75
Study 24268208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 2600
Study 24268208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2600
Study 21546216 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin 100mg twice a day for 10 weeks
Number of subjects: 66
Study 21546216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 18439596 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant follicle-stimulating hormone (FSH)
Number of subjects: 30
Study 18439596 — intervention group
Group type: COMPARATOR
Intervention: human (hMG)
Number of subjects: 30
Study 17481615 — intervention group
Group type: EXPERIMENTAL
Intervention: 750-mug tablets (2 tablets of 0.75 mg each)
Number of subjects: 0
Study 17481615 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-microg minipills (50 minipills)
Number of subjects: 0
Study 15364687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 70
Study 15364687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11677390 — intervention group
Group type: EXPERIMENTAL
Intervention: Four experimental techniques involving cues (locations, role relationships, personal timeline, and partners recalled prior to cues)
Number of subjects: 139
Study 11677390 — intervention group
Group type: COMPARATOR
Intervention: Alphabetic cues (control technique)
Number of subjects: 139
Study 11677390 — intervention group
Group type: EXPERIMENTAL
Intervention: All five techniques administered to another 19 participants
Number of subjects: 139
Study 9840526 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin 60 mg/m2 and epirubicin 110 mg/m2 on Day 1 for 2-3 cycles) followed by radiotherapy (66-74 Gy to primary tumor, median 71 Gy; 60-76 Gy to neck, median 66 Gy)
Number of subjects: 334
Study 9840526 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin and epirubicin) followed by radiotherapy
Number of subjects: 334
Study 9840526 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (66-74 Gy to primary tumor, median 71 Gy; 60-76 Gy to neck, median 66 Gy)
Number of subjects: 334
Study 7920755 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with amenorrhea and normal prolactin (PRL) levels
Number of subjects: 252
Study 7920755 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with galactorrhea alone
Number of subjects: 252
Study 7920755 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with amenorrhea
Number of subjects: 252
Study 7920755 — intervention group
Group type: COMPARATOR
Intervention: Matched controls of patients with amenorrhea and normal PRL
Number of subjects: 252
Study 7920755 — intervention group
Group type: COMPARATOR
Intervention: Matched controls of patients with galactorrhea alone
Number of subjects: 252
Study 3186777 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol-marine (containing desaturated n-6 and n-3 essential fatty acids)
Number of subjects: 25
Study 3186777 — intervention group
Group type: COMPARATOR
Intervention: Sunflower seed and linseed oil capsules
Number of subjects: 25
Study 86666 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial prophylaxis (metronidazole and kanamycin)
Number of subjects: 93
Study 86666 — intervention group
Group type: COMPARATOR
Intervention: Oral antimicrobial prophylaxis (metronidazole and kanamycin)
Number of subjects: 93
Study 30369297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid (15 min NTS followed by 15 min NMES)
Number of subjects: 43
Study 30369297 — intervention group
Group type: COMPARATOR
Intervention: NMES (30 min)
Number of subjects: 43
Study 30369297 — intervention group
Group type: COMPARATOR
Intervention: NTS (30 min)
Number of subjects: 43
Study 28435054 — intervention group
Group type: EXPERIMENTAL
Intervention: Palucorcel (human umbilical tissue-derived cells) administered in 33 eyes
Number of subjects: 35
Study 28435054 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 35
Study 26054656 — intervention group
Group type: EXPERIMENTAL
Intervention: PSAs with fear appeals
Number of subjects: 805
Study 26054656 — intervention group
Group type: EXPERIMENTAL
Intervention: PSAs with humor appeals
Number of subjects: 805
Study 26054656 — intervention group
Group type: EXPERIMENTAL
Intervention: PSAs with nurturance appeals
Number of subjects: 805
Study 26054656 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no emotional appeal)
Number of subjects: 805
Study 23738607 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% salmon egg extract
Number of subjects: 66
Study 23738607 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% salmon egg extract
Number of subjects: 66
Study 23738607 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% and 5% salmon egg extract
Number of subjects: 66
Study 23738607 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 66
Study 23148981 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care approach with outreach health coach
Number of subjects: 22
Study 23148981 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study 20227549 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone followed 48 h later by 400 mcg oral misoprostol (Group 1)
Number of subjects: 122
Study 20227549 — intervention group
Group type: EXPERIMENTAL
Intervention: 800‐mcg intravaginal single‐dose misoprostol (Group 2)
Number of subjects: 122
Study 17272435 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty
Number of subjects: 60
Study 17272435 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 60
Study 15656879 — intervention group
Group type: EXPERIMENTAL
Intervention: warfarin 1.25 mg plus aspirin 75 mg daily
Number of subjects: 3300
Study 15656879 — intervention group
Group type: COMPARATOR
Intervention: aspirin 75 mg alone
Number of subjects: 3300
Study 11893234 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 to 50 mg/day
Number of subjects: 0
Study 11893234 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 to 40 mg/day
Number of subjects: 0
Study 11893234 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 to 60 mg/day
Number of subjects: 0
Study 11893234 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 10373134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (12 microg twice a day)
Number of subjects: 32
Study 10373134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8554777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 10
Study 8554777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2230910 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g mezlocillin and 200 mg netilmicin as an i.v. bolus before implantation
Number of subjects: 552
Study 2230910 — intervention group
Group type: COMPARATOR
Intervention: 2 g mezlocillin before and then 6 and 12 hours after surgery and 200 mg netilmicin before and then 12 hours after implantation
Number of subjects: 552
Study 443916 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy without drainage (PCV)
Number of subjects: 194
Study 443916 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy-antrectomy and Billroth I anastomosis (SV‐A‐B I)
Number of subjects: 194
Study 31034455 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise adherence intervention
Number of subjects: 90
Study 31034455 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary rehabilitation
Number of subjects: 90
Study 29210892 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Aid (DCogA) projected on anesthesia information management system
Number of subjects: 30
Study 29210892 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to hard copy of the cognitive aid
Number of subjects: 30
Study 29210892 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Aid (DCogA)
Number of subjects: 30
Study 29210892 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 26002111 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy (3 cycles followed by surgery and then 3 cycles of completion chemotherapy)
Number of subjects: 552
Study 26002111 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery (followed by 6 cycles of chemotherapy)
Number of subjects: 552
Study 26002111 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 552
Study 26002111 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery
Number of subjects: 552
Study 23500609 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker treatment
Number of subjects: 381
Study 23500609 — intervention group
Group type: COMPARATOR
Intervention: No beta blocker treatment
Number of subjects: 381
Study 21257657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 9014
Study 21257657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 21257657 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring cholesterol concentration
Number of subjects: 9014
Study 19240703 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume phosphate solution (75 ml)
Number of subjects: 5
Study 19240703 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume sulfate solution (equimolar dose)
Number of subjects: 5
Study 19240703 — intervention group
Group type: COMPARATOR
Intervention: PEG (polyethylene glycol) lavage solution (4 liters)
Number of subjects: 5
Study 16698476 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-factor customized profile (custom-Q study group)
Number of subjects: 35
Study 16698476 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided customized ablation (control group)
Number of subjects: 35
Study 15545201 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fluid intake (60 ml/kg body weight per day)
Number of subjects: 30
Study 15545201 — intervention group
Group type: COMPARATOR
Intervention: Normal fluid intake (30 ml/kg body weight per day)
Number of subjects: 30
Study 11552354 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (aerobic, dynamic strengthening exercises)
Number of subjects: 18
Study 11552354 — intervention group
Group type: COMPARATOR
Intervention: Alternative programs (such as health education)
Number of subjects: 18
Study 9407480 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR intervention
Number of subjects: 326
Study 9407480 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 326
Study 8135486 — intervention group
Group type: EXPERIMENTAL
Intervention: ACV (Adriamycin, cyclophosphamide, and vindesine)
Number of subjects: 90
Study 8135486 — intervention group
Group type: COMPARATOR
Intervention: NCV (Mitoxantrone, cyclophosphamide, and vindesine)
Number of subjects: 90
Study 2441203 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 25 mg every 8 hours (t.i.d.)
Number of subjects: 16
Study 2441203 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (D) 0.25 mg once daily
Number of subjects: 16
Study 2441203 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT)
Number of subjects: 16
Study 2441203 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (D)
Number of subjects: 16
Study 2441203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 16
Study 29624476 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies targeting pro-inflammatory pathways (e.g., IL-12/23 axis, IL-6 pathway, Janus Kinase inhibitors)
Number of subjects: 0
Study 29624476 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies modulating anti-inflammatory pathways (e.g., TGF-β1)
Number of subjects: 0
Study 29624476 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs targeting leukocyte adhesion and migration (e.g., α4β7 integrins, MAdCAM-1)
Number of subjects: 0
Study 29624476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingosine-1-phosphate (S1P) receptor modulators
Number of subjects: 0
Study 29624476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapies using mesenchymal stem cells or engineered T regs
Number of subjects: 0
Study 27363734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (InGaAIP laser, 660 nanometer, 40 milliwatts of power, 5 Joules per square centimeter of energy density for 5 seconds each, total energy = 0.6 Joules)
Number of subjects: 59
Study 27363734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 59
Study 24411004 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer software intervention where intervention batches are examined in the opposite order by the two readers (one forwards, one backwards)
Number of subjects: 44
Study 24411004 — intervention group
Group type: COMPARATOR
Intervention: Standard practice where control batches are read in the same order by both readers
Number of subjects: 44
Study 24411004 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 44
Study 23465566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-eat cereal (RTEC) consumption
Number of subjects: 625
Study 20622412 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude toward establishing smoke zones in public places
Number of subjects: 1000
Study 20622412 — intervention group
Group type: COMPARATOR
Intervention: Smoking habit
Number of subjects: 1000
Study 20622412 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 1000
Study 18258487 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 101
Study 18258487 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 101
Study 16046924 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized motor-skill analyser (CMSA) for the arm
Number of subjects: 27
Study 11973012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (maximum dose of 400 mg)
Number of subjects: 30
Study 11973012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10403341 — intervention group
Group type: EXPERIMENTAL
Intervention: PM‐YF vaccine
Number of subjects: 211
Study 10403341 — intervention group
Group type: COMPARATOR
Intervention: W‐YF vaccine (Arilvax)
Number of subjects: 211
Study 10403341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 211
Study 7745516 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 224